Federal regulators said Monday a Cryocor Corp. device that uses extreme cold to treat defective heart muscle did not show overwhelmingly safe or effective results in company studies. The company’s shares dropped sharply.
Federal regulators said Monday a Cryocor Corp. device that uses extreme cold to treat defective heart muscle did not show overwhelmingly safe or effective results in company studies. The company’s shares dropped sharply.
